Mindstrong Health, a Palo Alto, CA-based healthcare company focused on improving brain health through measurement science, secured a B round financing of $15m.
A syndicate of investors and healthcare innovators participated in the round.
The company, which has raised a total of $29m to date, intends to use the capital to scale the business and advance commercial deployments with its partners across healthcare verticals.
Founded by Paul Dagum, MD, PhD, Tom Insel, MD, and Rick Klausner, MD, Mindstrong Health develops comprehensive care pathways based on passively-collected, continuous and objective measures of cognitive function and mood. Solutions include a patient-facing app, a provider-facing product, and clinical services that leverage its telehealth enabled measurement science and engagement platform.
Mindstrong is partnered with leading organizations committed to advancing medical innovation and improving healthcare delivery for patients, including pharmaceutical companies, large payers and providers, large employers, and state and county governments, in addition to top-tier academic institutions for clinical research.
This year, the company announced a partnership with Takeda Pharmaceutical Company Limited to apply Mindstrong’s technology to identify digital biomarkers in schizophrenia and treatment-resistant depression. Mindstrong is also partnered with Blackthorn Therapeutics.